Metabolic modeling of gut microbiota in high-fat diet-induced nonalcoholic steatohepatitis through barrier dysfunction and shaping of intrahepatic immunity are ameliorated by VSL#3 supplementation
Nonalcoholic fatty liver disease (NAFLD), which is the most common liver disease, is associated with type 2 diabetes mellitus and metabolic syndrome. Although there is no consensus on the treatment of
Non-alcoholic steatohepatitis (NASH) represents a major economic burden and is characterized by triglyceride accumulation, inflammation, and fibrosis. No pharmacological agents are currently approved